• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Revvity Inc.

    3/12/25 8:05:23 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    DEFA14A 1 d925831ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒       Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Revvity, Inc.

    (Name of Registrant as Specified in its Charter)

    Not applicable.

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒   No fee required.
    ☐   Fee paid previously with preliminary materials.
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

                    
                         
       

     

    Your Vote Counts!

          

           LOGO

     

    REVVITY, INC.

     

    77 4TH AVENUE

    WALTHAM, MA 02451

     

     

    REVVITY, INC.

     

    2025 Annual Meeting

    Vote by April 21, 2025 11:59 PM ET. For shares held in a

    Plan, vote by April 17, 2025 11:59 PM ET.

     

         
       
      LOGO       
       
       
         
         

     

         
     
     
         
     
         

    V62071-P24552-Z89246

                  
               

    You invested in REVVITY, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on April 22, 2025.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report OR you can receive a free paper or email copy of the material(s) by requesting prior to April 8, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

     

     

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

     

     Voting Items  

    Board

    Recommends

     

    1.

     

    To elect ten nominees for director for terms of one year each:

     

    Nominees:

     

         
     

    1a.

      Peter Barrett, PhD   LOGO   For
     

    1b.

      Samuel R. Chapin   LOGO   For
     

    1c.

      Michael A. Klobuchar   LOGO   For
     

    1d.

      Michelle McMurry-Heath, MD, PhD   LOGO   For
     

    1e.

      Alexis P. Michas   LOGO   For
     

    1f.

      Prahlad R. Singh, PhD   LOGO   For
     

    1g.

      Sophie V. Vandebroek, PhD   LOGO   For
     

    1h.

      Michel Vounatsos   LOGO   For
     

    1i.

      Frank Witney, PhD   LOGO   For
     

    1j.

      Pascale Witz   LOGO   For
     

    2.

      To ratify the selection of Deloitte & Touche LLP as Revvity’s independent registered public accounting firm for the current fiscal year.   LOGO   For
     

    3.

      To approve, by non-binding advisory vote, our executive compensation.   LOGO   For
     

    4.

      To approve amendments to Revvity’s Restated Articles of Organization, as amended, and Amended and Restated By- laws to implement a majority voting standard for specified corporate actions.   LOGO   For
     

    5.

      To approve the shareholder proposal regarding ability to call a special shareholder meeting, if properly presented at the annual meeting.   LOGO   Against

    NOTE: The proxies are authorized to vote, in their discretion, upon such other business as may properly come before the meeting or any adjournment or postponement thereof.

         

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V62072-P24552-Z89246           

    Get the next $RVTY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AstroNova Sends Letter to Shareholders Highlighting Growth Strategy and Strength of Board

      AstroNova is at critical inflection point in its strategic progress to create meaningful competitive advantages for the Product Identification segment and drive strong, sustainable growth, improved profitability and address measurably larger addressable markets Askeladden/Patel's misguided, upstart campaign is disrupting progress and his unfit nominees stand to siderail advancement Urges shareholders to vote "FOR" ONLY AstroNova's Board nominees on the WHITE proxy card Current leadership has transformed AstroNova's capabilities, product mix, and scale, delivering 7.5% compound annual revenue growth since Gregory Woods' appointment as CEO AstroNova, Inc. (NASDAQ:ALOT), a leading innovat

      5/19/25 5:00:00 PM ET
      $ALNT
      $ALOT
      $BWA
      $RVTY
      Electrical Products
      Industrials
      Computer peripheral equipment
      Technology
    • Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

      The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease and therapeutic drug monitoring Revvity, Inc. (NYSE:RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously ru

      5/19/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity to Present at Upcoming Investor Conferences

      Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will b

      4/30/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Revvity Inc.

      10-Q - REVVITY, INC. (0000031791) (Filer)

      5/6/25 4:07:57 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      4/28/25 7:16:22 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 8-K filed by Revvity Inc.

      8-K - REVVITY, INC. (0000031791) (Filer)

      4/25/25 4:06:40 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Revvity upgraded by UBS with a new price target

      UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

      5/1/25 7:42:49 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity downgraded by Bernstein with a new price target

      Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

      1/10/25 8:41:17 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity upgraded by BofA Securities with a new price target

      BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

      12/13/24 8:43:02 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2025

      Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu

      4/28/25 6:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity Board Declares Quarterly Dividend

      The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec

      4/24/25 4:05:00 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity to Hold Earnings Call on Monday, April 28, 2025

      Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

      4/3/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Vandebroek Sophie V. was granted 2,412 shares, increasing direct ownership by 90% to 5,088 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:18 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Klobuchar Michael A was granted 2,412 shares, increasing direct ownership by 90% to 5,088 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:13 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Chapin Samuel R. was granted 2,412 shares, increasing direct ownership by 13% to 20,396 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:19 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 4:30:07 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:28:28 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Revvity Inc.

      SC 13G - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:22:34 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials